Update and latest advances in antiretroviral therapy
L Menéndez-Arias, R Delgado - Trends in pharmacological sciences, 2022 - cell.com
Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-
1) infection has reached pandemic proportions. Forty years later, research has led to the …
1) infection has reached pandemic proportions. Forty years later, research has led to the …
[HTML][HTML] Approved HIV reverse transcriptase inhibitors in the past decade
G Li, Y Wang, E De Clercq - Acta Pharmaceutica Sinica B, 2022 - Elsevier
HIV reverse transcriptase (RT) inhibitors are the important components of highly active
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …
[图书][B] Improving antenatal iron-containing supplementation indicators: a report on key informant interviews, an online survey and DHS data analyses
World Health Organization… - 2020 - books.google.com
Page 1 IMPROVING ANTENATAL IRON-CONTAINING SUPPLEMENTATION INDICATORS
REPORT OF KEY INFORMANT INTERVIEWS, ONLINE SURVEY, AND DHS DATA …
REPORT OF KEY INFORMANT INTERVIEWS, ONLINE SURVEY, AND DHS DATA …
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities
The effectiveness of HIV pre-exposure prophylaxis (PrEP) hinges on adherence, which has
been restricted by multifaceted barriers. Uptake of PrEP has been impeded by poor access …
been restricted by multifaceted barriers. Uptake of PrEP has been impeded by poor access …
Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges
V Agrahari, SM Anderson, MM Peet… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Poor or inconsistent adherence to daily oral pre-exposure prophylaxis (PrEP)
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …
has emerged as a key barrier to effective HIV prevention. The advent of potent long-acting …
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among …
Background Half of new HIV acquisitions in Africa occur in adolescent girls and young
women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus …
women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus …
Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention
SA Krovi, LM Johnson, E Luecke, SL Achilles… - Advanced drug delivery …, 2021 - Elsevier
Worldwide, women face compounding reproductive health risks, including human
immunodeficiency virus (HIV), sexually-transmitted infections (STIs), and unintended …
immunodeficiency virus (HIV), sexually-transmitted infections (STIs), and unintended …
[HTML][HTML] Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection
Adherence to daily oral antiretroviral therapy (ART) is a barrier to both treatment and
prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life …
prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life …
Long-acting injectable cabotegravir for HIV prevention: what do we know and need to know about the risks and consequences of cabotegravir resistance?
UM Parikh, CA Koss, JW Mellors - Current HIV/AIDS Reports, 2022 - Springer
Abstract Purpose of Review Cabotegravir is a potent integrase strand transfer inhibitor
(INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB …
(INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB …
Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap
Pregnant and breastfeeding populations are at substantial risk of acquiring HIV in some
settings, yet are underrepresented in clinical trials of new pre-exposure prophylaxis (PrEP) …
settings, yet are underrepresented in clinical trials of new pre-exposure prophylaxis (PrEP) …